Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-2
Closed -$1K 478
2019
Q1
$1K Buy
2
+1
+100% +$82 ﹤0.01% 450
2018
Q4
$1K Buy
+1
New +$88 ﹤0.01% 416
2017
Q3
Sell
-5
Closed -$7K 366
2017
Q2
$7K Buy
+5
New +$336 ﹤0.01% 364
2017
Q1
Sell
-23
Closed -$8K 305
2016
Q4
$8K Buy
23
+7
+44% +$427 ﹤0.01% 251
2016
Q3
$4K Sell
16
-3
-16% -$194 ﹤0.01% 255
2016
Q2
$7K Buy
+19
New +$1.16K ﹤0.01% 252

Other funds holding ABBV

Kovack Advisors's ABBV Position: Q2 2026 in Review

Kovack Advisors reduced its AbbVie (ABBV) stake by 25% in Q2 2026, selling an estimated $1.59M and leaving 22,380 shares worth $5.62M. The position accounts for 0.27% of the portfolio, ranked #72.

Kovack Advisors first reported a position in ABBV in Q3 2015 and has held it in 43 quarters since. The position peaked at $7.06M in Q4 2025. 1,884 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Kovack Advisors held 22,380 shares of AbbVie worth $5.62M as of Q2 2026.
  • Kovack Advisors sold 7,404 AbbVie shares in Q2 2026, an estimated $1.59M.
  • AbbVie made up 0.27% of Kovack Advisors's portfolio in Q2 2026, its #72 holding.
  • Kovack Advisors first reported a position in AbbVie in Q3 2015 and has held it in 43 quarters since.
  • Kovack Advisors's AbbVie position peaked at $7.06M in Q4 2025.
  • 1,884 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.